Clinical Trial Update: SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE） [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating the combination of stereotactic body radiotherapy (SBRT) with a PD-1 antibody in unresectable locally recurrent rectal canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Unresectable Locally Recurrent Rectal Cancer | Phase 2 | Status: RECRUITING